HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Identification of a basal-like subtype of breast ductal carcinoma in situ.

Abstract
Microarray profiling of invasive breast carcinomas has identified subtypes including luminal A, luminal B, HER2-overexpressing, and basal-like. The poor-prognosis, basal-like tumors have been immunohistochemically characterized as estrogen receptor (ER)-negative, HER2/neu-negative, and cytokeratin 5/6-positive and/or epidermal growth factor receptor (EGFR)-positive. The aim of this study was to determine the prevalence of basal-like ductal carcinoma in situ in a population-based series of cases using immunohistochemical surrogates. A total of 245 pure ductal carcinoma in situ cases from a population-based, case-control study were evaluated for histologic characteristics and immunostained for ER, HER2/neu, EGFR, cytokeratin 5/6, p53, and Ki-67. The subtypes were defined as: luminal A (ER+, HER2-), luminal B (ER+, HER2+), HER2 positive (ER-, HER2+), and basal-like (ER-, HER2-, EGFR+, and/or cytokeratin 5/6+). The prevalence of breast cancer subtypes was basal-like (n = 19 [8%]); luminal A, n = 149 (61%); luminal B, n = 23 (9%); and HER2+/ER-, n = 38 (16%). Sixteen tumors (6%) were unclassified (negative for all 4 defining markers). The basal-like subtype was associated with unfavorable prognostic variables including high-grade nuclei (P < .0001), p53 overexpression (P < .0001), and elevated Ki-67 index (P < .0001). These studies demonstrate the presence of a basal-like in situ carcinoma, a potential precursor lesion to invasive basal-like carcinoma.
AuthorsChad A Livasy, Charles M Perou, Gamze Karaca, David W Cowan, Diane Maia, Susan Jackson, Chiu-Kit Tse, Sarah Nyante, Robert C Millikan
JournalHuman pathology (Hum Pathol) Vol. 38 Issue 2 Pg. 197-204 (Feb 2007) ISSN: 0046-8177 [Print] United States
PMID17234468 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Keratin-5
  • Keratin-6
  • Ki-67 Antigen
  • Receptors, Estrogen
  • Tumor Suppressor Protein p53
  • Receptor, Epidermal Growth Factor
  • Receptor, ErbB-2
Topics
  • Adult
  • Aged
  • Breast Neoplasms (classification, metabolism, pathology)
  • Carcinoma, Intraductal, Noninfiltrating (classification, metabolism, pathology)
  • Female
  • Humans
  • Immunohistochemistry
  • Keratin-5 (analysis)
  • Keratin-6 (analysis)
  • Ki-67 Antigen (analysis)
  • Middle Aged
  • Prognosis
  • Receptor, Epidermal Growth Factor (analysis)
  • Receptor, ErbB-2 (analysis)
  • Receptors, Estrogen (analysis)
  • Tissue Array Analysis
  • Tumor Suppressor Protein p53 (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: